The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Zhejiang University
Celon Pharma SA
University Health Network, Toronto
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Centre Georges Francois Leclerc
University of California, Davis
Lebanese University
Institut Mutualiste Montsouris
Peking Union Medical College Hospital
Kineta Inc.
Region Skane
Angiodynamics, Inc.
LynxDx
Wuhan Ammunition Life-tech Co., Ltd
Blue Note Therapeutics
Revolution Medicines, Inc.
Imperial College London
Hospital de Clinicas de Porto Alegre
University College, London
Assistance Publique - Hôpitaux de Paris
Hellenic GenitoUrinary Cancer Group
Waterford Instituate of Technology
British Columbia Cancer Agency
Duke-NUS Graduate Medical School
Koelis
Butantan Institute
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
SpeciCare
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Azienda Ospedaliero-Universitaria di Modena
Royal Marsden NHS Foundation Trust
Hamlet Pharma AB
Guy's and St Thomas' NHS Foundation Trust
Instituto do Cancer do Estado de São Paulo
Università Politecnica delle Marche
Amsterdam UMC, location VUmc
IVI Barcelona
Rigshospitalet, Denmark
Cambridge University Hospitals NHS Foundation Trust
SonaCare Medical
Tianjin Medical University Second Hospital
British Columbia Cancer Agency
Merrimack Pharmaceuticals
Mansoura University
Mansoura University
University Hospital, Strasbourg, France
Instituto Nacional de Cancerologia de Mexico
Ottawa Hospital Research Institute
Assistance Publique - Hôpitaux de Paris
Arno Therapeutics